Meeting
2019 ASCO Annual Meeting
Radiomics features to identify distinct subtypes of triple-negative breast cancers.
Authors
Haruka Itakura
Stanford Univ Medcl Ctr, Stanford, CA
Haruka Itakura , Debra M. Ikeda , Satoko Okamoto , Shu-Tian Chen , Blaine Rister , Dev Gude , Sarah A. Mattonen , Emel Alkim , Julia Todderud , Emil Schueler , Daniel Rubin , George W. Sledge Jr., Allison W. Kurian
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics and Tumor Biology (Nonimmuno)
Track
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Sub Track
Molecular Diagnostics and Imaging
Citation
J Clin Oncol 37, 2019 (suppl; abstr 3069)
DOI
10.1200/JCO.2019.37.15_suppl.3069
Abstract #
3069
Poster Bd #
61
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
A radiomic-based predictive model of lung adenocarcinoma brain metastases and molecular subtypes.
First Author: Xiancheng Wu
Poster
2020 ASCO Virtual Scientific Program
Prognostic impact of high stromal tumor-infiltrating lymphocytes (sTIL) in the absence of pathologic complete response (pCR) to neoadjuvant therapy (NAT) in early stage triple negative breast cancer (TNBC).
First Author: Nour Abuhadra
Poster
2020 ASCO Virtual Scientific Program
Neoadjuvant docetaxel + carboplatin versus epirubicin+cyclophosphamide followed by docetaxel in triple-negative, early-stage breast cancer (NeoCART): Results from a multicenter, randomized controlled, open-label, phase II trial.
First Author: Liulu Zhang
Poster
2020 ASCO Virtual Scientific Program
CT and PET radiomic features associated with major pathologic response to neoadjuvant immunotherapy in early-stage non-small cell lung cancer (NSCLC).
First Author: Erica C. Nakajima